Company Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.
In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools.
The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations.
It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries.
The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015.
Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | Jul 23, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 676 |
| CEO | Dr. Wenbin Jiang Ph.D. |
Contact Details
Address: 47215 Lakeview Boulevard Fremont, California 94538 United States | |
| Phone | (877) 922-9835 |
| Website | cytekbio.com |
Stock Details
| Ticker Symbol | CTKB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001831915 |
| CUSIP Number | 23285D109 |
| ISIN Number | US23285D1090 |
| Employer ID | 47-2547526 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wenbin Jiang Ph.D. | President, Chief Executive Officer and Chairman of the Board |
| Dr. Ming Yan Ph.D. | Chief Technology Officer and Director |
| Valerie T. Barnett J.D. | Chief Legal Officer |
| William D. McCombe | Chief Financial Officer |
| Chris Williams | Chief Operating Officer |
| Dr. Allen B. Poirson Ph.D. | Senior Vice President of Business and Corporate Development |
| Dr. Philippe Busque Ph.D. | Senior Vice President of Global Sales and Services |
| Patrik Sebastian Jeanmonod | Head of Corporate Development Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | 144 | Filing |
| Mar 19, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 144 | Filing |
| Mar 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |